Enhancing endothelial progenitor cell function through selective estrogen receptor modulation: A potential approach to cardiovascular risk reduction

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 8, Issue 3, 2010, Pages 147-155

  Cignarella, Andrea ^a   Fadini, Gian Paolo ^b  

^a Department of Pharmacology and Anesthesiology   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Atherosclerosis; Regeneration; Reproductive system; Stem cells

Indexed keywords

1,3,5 TRIS(4 HYDROXYPHENYL) 4 PROPYLPYRAZOLE; ANTIESTROGEN; BAZEDOXIFENE; CHOLESTEROL; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR; LASOFOXIFENE; RALOXIFENE; TAMOXIFEN;

ARTERY ENDOTHELIUM; ARTICLE; BREAST CANCER; CANCER PATIENT; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL; CELL FUNCTION; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; FATALITY; HORMONAL THERAPY; HUMAN; MAMMAL; METABOLITE; NONHUMAN; OBESITY; OSTEOPOROSIS; POSTMENOPAUSE; STEM CELL; STROKE; THROMBOEMBOLISM; TISSUE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

CARDIOVASCULAR DISEASES; ENDOTHELIAL CELLS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; POSTMENOPAUSE; RISK REDUCTION BEHAVIOR; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 77954710584     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152510791698406     Document Type: Article

References (77)

1. Deroo, B.J.; Korach, K.S. Estrogen receptors and human disease. J.Clin. Invest., 2006, 116, 561-570.
2. Farquhar, C.; Marjoribanks, J.; Lethaby, A.; Suckling, J.A.; Lam-berts, Q. Long term hormone therapy for perimenopausal andpostmenopausal women. Cochrane Database Syst. Rev., 2009, 2,CD004143.
3. Rossouw, J.E.; Anderson, G.L.; Prentice, R.L.; LaCroix, A.Z.; Kooperberg, C.; Stefanick, M.L.; Jackson, R.D.; Beresford, S.A.; Howard, B.V.; Johnson, K.C.; Kotchen, J.M.; Ockene, J.; WritingGroup for the Women's Health Initiative Investigators. Risks andbenefits of estrogen plus progestin in healthy postmenopausalwomen: principal results from the Women's Health Initiative ran-domized controlled trial. JAMA, 2002, 288, 321-333.
4. Khalil, R.A. Potential approaches to enhance the effects of estrogenon senescent blood vessels and postmenopausal cardiovascular dis-ease. Cardiovasc. Hematol. Agents Med. Chem., 2010, 8, 29-46.
5. Rosenzweig, A. Circulating endothelial progenitors - cells as biomarkers. N. Engl. J. Med., 2005, 353, 1055-1057.
6. Riggs BL.; Hartmann, L.C. Selective estrogen-receptor modulators- mechanisms of action and application to clinical practice. N.Engl. J. Med., 2003, 348, 618-629.
7. Shang, Y.; Brown, M. Molecular determinants for the tissue speci-ficity of SERMs. Science, 2002, 295, 2465-2468.
8. Kawagoe, J.; Ohmichi, M.; Tsutsumi, S.; Ohta, T.; Takahashi, K.; Kurachi, H. Mechanism of the divergent effects of estrogen on thecell proliferation of human umbilical endothelial versus aorticsmooth muscle cells. Endocrinology, 2007, 148, 6092-6099.
9. Billon-Galés, A.; Fontaine, C.; Filipe, C.; Douin-Echinard, V.; Fouque, M.J.; Flouriot, G.; Gourdy, P.; Lenfant, F.; Laurell, H.; Krust, A.; Chambon, P.; Arnal, J.F. The transactivating function 1of estrogen receptor is dispensable for the vasculoprotective ac-tions of 17 -estradiol. Proc. Natl. Acad. Sci. USA, 2009, 106, 2053-2058.
10. Umetani, M.; Domoto, H.; Gormley, A.K.; Yuhanna, I.S.; Cum-mins, C.L.; Javitt, N.B.; Korach, K.S.; Shaul, P.W.; MangelsdorfDJ. 27-Hydroxycholesterol is an endogenous SERM that inhibitsthe cardiovascular effects of estrogen. Nat. Med., 2007, 13, 1185-1192.
11. Duane, W.C.; Javitt, N.B. 27-hydroxycholesterol: production ratesin normal human subjects. J. Lipid Res., 1999, 40, 1194-1199.
12. Vitale, C.; Mendelsohn, M.E.; Rosano, G.M. Gender differences inthe cardiovascular effect of sex hormones. Nat. Rev. Cardiol.,2009, 6, 532-542.
13. Dubey, R.K.; Imthurn, B.; Barton, M.; Jackson, E.K. Vascularconsequences of menopause and hormone therapy: importance oftiming of treatment and type of estrogen. Cardiovasc. Res., 2005,66, 295-306.
14. Writing Group on behalf of Workshop Consensus Group. Aging,menopause, cardiovascular disease, and HRT - InternationalMenopause Society Consensus Statement. Climacteric, 2009, 12,368-377.
15. Grodstein, F.; Manson, J.E.; Stampfer, M.J. Hormone therapyand coronary heart disease: the role of time since menopause andage at hormone initiation. J. Womens Health (Larchmt), 2006, 15,35-44.
16. Rossouw, J.E.; Prentice, R.L.; Manson, J.E.; Wu, L.; Barad, D.; Barnabei, V.M.; Ko M.; LaCroix, A.Z.; Margolis, K.L.; Stefanick, M.L. Postmenopausal hormone therapy and risk of cardiovasculardisease by age and years since menopause. JAMA, 2007, 297,1465-1477.
17. Toh, S.; Hernández-Díaz, S.; Logan, R.; Rossouw, J.E.; Hernán, M.A. CHD in postmenopausal recipients of estrogen plus progestintherapy: does the increased risk ever disappear? A randomized trial.Ann. Intern. Med., 2010, 152, 211-217.
18. Grodstein, F.; Manson, J.E.; Stampfer, M.J.; Rexrode, K. Post-menopausal hormone therapy and stroke: role of time since meno-pause and age at initiation of hormone therapy. Arch. Intern.Med., 2008, 168, 861-866.
19. Hendrix, S.L.; Wassertheil-Smoller, S.; Johnson, K.C.; Howard, B.V.; Kooperberg, C.; Rossouw, J.E.; Trevisan, M.; Aragaki, A.; Baird, A.E.; Bray, P.F, Buring, J.E.; Criqui, M.H.; Herrington, D.; Lynch, J.K.; Rapp, S.R.; Torner, J.; WHI Investigators. Effects ofconjugated equine estrogen on stroke in the Women's Health Initia-tive Circulation, 2006, 113, 2425-2434.
20. Harman, S.M.; Brinton, E.A.; Cedars, M.; Lobo, R.; Manson, J.E.; Merriam, G.R.; Miller, V.M.; Naftolin, F.; Santoro, N. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric, 2005, 8, 3-12.
21. Fisher, B.; Costantino, J.P.; Redmond, C.K.; Fisher, E.R.; Wicker-ham, D.L.; Cronin, W.M. Endometrial cancer in tamoxifen-treatedbreast cancer patients: findings from the National Surgical Adju-vant Breast and Bowel Project (NSABP) B-14. J. Natl. CancerInst., 1994, 86, 527-537.
22. Black, L.J.; Sato, M.; Rowley, E.R.; Magee, D.E.; Bekele, A.; Williams, D.C.; Cullinan, G.J.; Bendele, R.; Kauffman, R.F.; Bensch, W.R.; Frolik, C.A.; Termine, J.D. Bryant, H.U.Raloxifene (LY139481 HCI) prevents bone loss and reduces serumcholesterol without causing uterine hypertrophy in ovariectomizedrats. J. Clin. Invest., 1994, 93, 63-69.
23. Cummings, S.R.; Eckert, S.; Krueger, K.A.; Grady, D.; Powles, T.J.; Cauley, J.A.; Norton, L.; Nickelsen, T.; Bjarnason, N.H.; Morrow, M.; Lippman, M.E.; Black, D.; Glusman, J.E.; Costa, A.; Jordan, V.C. The effect of raloxifene on risk of breast cancer inpostmenopausal women: results from the MORE randomized trial -Multiple outcomes of raloxifene evaluation. JAMA, 1999, 281,2189-2197.
24. Pinna, C.; Bolego, C.; Sanvito, P.; Pelosi, V.; Baetta, R.; Corsini, A.; Gaion, R.M.; Cignarella, A. Raloxifene elicits combined rapidvasorelaxation and long-term anti-inflammatory actions in rat aorta.J. Pharmacol. Exp. Ther., 2006, 319, 1444-1451.
25. Cushman, M.; Costantino, J.P.; Tracy, R.P.; Song, K.; Buckley, L.; Roberts, J.D.; Krag, D.N. Tamoxifen and cardiac risk factors inhealthy women: suggestion of an anti-inflammatory effect. Arterio-scler Thromb. Vasc. Biol., 2001, 21, 255-261.
26. Braithwaite, R.S.; Chlebowski, R.T.; Lau, J.; George, S.; Hess, R.; Col, N.F. Meta-analysis of vascular and neoplastic events associ-ated with tamoxifen. J. Gen. Intern. Med.; 2003, 18, 937-947.
27. Hozumi, Y.; Kawano, M.; Hakamata, Y.; Miyata, M.; Jordan, V.C.Tamoxifen inhibits lipoprotein activity: in vivo and in vitro studies.Horm. Res., 2000, 53, 36-39.
28. Grainger, D.J.; Schofield, P.M. Tamoxifen for the preventionof myocardial infarction in humans: preclinical and early clinicalevidence. Circulation, 2005, 112, 3018-3024.
29. Clarke, S.C.; Schofield, P.M.; Grace, A.A.; Metcalfe, J.C.; Kirschenlohr, H.L. Tamoxifen effects on endothelial function andcardiovascular risk factors in men with advanced atherosclerosis.Circulation, 2001, 103, 1497-1502.
30. Stamatelopoulos, K.; Lekakis, J.; Poulakaki, N.; Papamichael, C.; Venetsanou, K.; Aznaouridis, K.; Protogerou, A.; Papaioannou, T.; Kumar, S.; Stamatelopoulos, S. Tamoxifen improves endothelialfunction and reduces carotid intima-media thickness in postmeno-pausal women. Am. Heart J., 2004, 147, 1093-1099.
31. Reis, S.E.; Costantino, J.P.; Wickerham, D.L.; Tan-Chiu, E.; Wang, J.; Kavanah, M. Cardiovascular effects of tamoxifen in womenwith and without heart disease: breast cancer prevention trial. Na-tional Surgical Adjuvant Breast and Bowel Project Breast CancerPrevention Trial Investigators. J. Natl. Cancer Inst., 2001, 93, 16-21.
32. Ridker, P.M.; Danielson, E.; Fonseca, F.A.; Genest, J.; Gotto, A.M., Jr.; Kastelein, J.J.; Koenig, W.; Libby, P.; Lorenzatti, A.J.; MacFadyen, J.G.; Nordestgaard, B.G.; Shepherd, J.; Willerson, J.T.; Glynn, R.J.; JUPITER Study Group. Rosuvastatin to preventvascular events in men and women with elevated C-reactive pro-tein. N. Engl. J. Med., 2008, 359, 2195-2207.
33. Lakoski, S.G.; Herrington, D.M. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review arti-cle. Climacteric, 2005, 8, 317-326.
34. Bray, P.F.; Larson, J.C.; Lacroix, A.Z.; Manson, J.; Limacher, M.C.; Rossouw, J.E.; Lasser, N.L.; Lawson, W.E.; Stefanick, M.L.; Langer, R.D.; Margolis, K.L. Women's Health Initiative Investiga-tors. Usefulness of baseline lipids and C-reactive protein in womenreceiving menopausal hormone therapy as predictors of treatment-related coronary events. Am. J. Cardiol., 2008, 101, 1599-1605.
35. Erlinger, T.P.; Platz, E.A.; Rifai, N.; Helzlsouer, K.J. C-reactiveprotein and the risk of incident colorectal cancer. JAMA, 2004, 291,585-590.
36. Nguyen, M.C.; Stewart, R.B.; Banerji, M.A.; Gordon, D.H.; Kral, J.G. Relationships between tamoxifen use, liver fat and body fatdistribution in women with breast cancer. Int. J. Obes. Rel. Metab.Disord., 2001, 25, 296-298.
37. Barrett-Connor, E.; Mosca, L.; Collins, P.; Geiger, M.J.; Grady, D.; Kornitzer, M.; McNabb, M.A.; Wenger, N.K. Raloxifene Use forThe Heart (RUTH) Trial Investigators. Effects of raloxifene oncardiovascular events and breast cancer in postmenopausal women.N. Engl. J. Med., 2006, 355, 125-137.
38. Barrett-Connor, E.; Grady, D.; Sashegyi, A.; Anderson, P.W.; Cox, D.A.; Hoszowski, K.; Rautaharju, P.; Harper, K.D.; MORE Investigators. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA, 2002, 287, 847-857.
39. Collins, P.; Mosca, L.; Geiger, M.J.; Grady, D.; Kornitzer, M.; Amewou-Atisso, M.G.; Effron, M.B.; Dowsett, S.A.; Barrett-Connor, E.; Wenger, N.K. Effects of the selective estrogen receptormodulator raloxifene on coronary outcomes in the Raloxifene Usefor The Heart trial: results of subgroup analyses by age and otherfactors. Circulation, 2009, 119, 922-930.
40. Wenger, N.K.; Barrett-Connor, E.; Collins, P.; Grady, D.; Kornit-zer, M.; Mosca, L.; Sashegyi, A.; Baygani, S.K.; Anderson, P.W.; Moscarelli, E. Baseline characteristics of participants in theRaloxifene Use for the Heart (RUTH) trial. Am. J. Cardiol., 2002,90, 1204-1210.
41. Mosca, L.; Grady, D.; Barrett-Connor, E.; Collins, P.; Wenger, N.; Abramson, B.L.; Paganini-Hill, A.; Geiger, M.J.; Dowsett, S.A.; Amewou-Atisso, M.; Kornitzer, M. Effect of raloxifene on strokeand venous thromboembolism according to subgroups in post-menopausal women at increased risk of coronary heart disease.Stroke, 2009, 40, 147-155.
42. Barrett-Connor, E.; Cox, D.A.; Song, J.; Mitlak, B.; Mosca, L.; Grady, D. Raloxifene and risk of stroke based on the Framinghamstroke risk score. Am. J. Med., 2009, 122, 754-761.
43. Viscoli, C.M.; Brass, L.M.; Kernan, W.N.; Sarrel, P.M.; Suissa, S.; Horwitz, R.I. A clinical trial of estrogen-replacement therapy after ischemic stroke. N. Engl. J. Med., 2006, 345, 1243-1249.
44. McClung, M.R.; Siris, E.; Cummings, S.; Bolognese, M.; Ettinger, M.; Moffett, A.; Emkey, R.; Day, W.; Somayaji, V.; Lee, A. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause, 2006, 13, 377-386.
45. Cummings, S.R.; Ensrud, K.; Delmas, P.D.; Lacroix, A.Z.; Vukicevic, S.; Reid, D.M.; Goldstein, S.; Sriram, U.; Lee, A.; Thompson, J.; Armstrong, R.A.; Thompson, D.D.; Powles, T.; Zanchetta, J.; Kendler, D.; Neven, P.; Eastell, R.; the PEARL Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N. Engl. J. Med., 2010, 362, 686-696.
46. Martino, S.; Disch, D.; Dowsett, S.A.; Keech, C.A.; Mershon, J.L. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr. Med. Res. Opin., 2005, 21, 1441-1452.
47. Walsh, B.W.; Paul, S.; Wild, R.A.; Dean, R.A.; Tracy, R.P.; Cox, D.A.; Anderson, P.W. The effects of raloxifene compared with hormone replacement therapy on homocysteine and C-reactive protein in healthy postmenopausal women: a randomized controlled trial. J. Clin. Endocrinol. Metab., 2000, 85, 214-218.
48. Lewiecki, E.M. Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis. Ther. Clin. Risk Manag., 2009, 5, 817-827.
49. Miller, P.; Chines, A.; Christiansen, C.; Hoeck, H.; Kendler, D.; Lewiecki, E.; Woodson, G.; Levine, A.B.; Constantine, G.; Delmas, P.D. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, doubleblind, placebo-, and active-controlled study. J. Bone Miner. Res., 2008, 23, 525-535.
50. Silverman, S.L.; Christiansen, C.; Genant, H.K.; Vukicevic, S.; Zanchetta, J.R.; de Villiers, T.J.; Constantine, G.D.; Chines, A.A. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J. Bone Min. Res., 2008, 23, 1923-1934.
51. Chang, K.C.; Wang, Y.; Bodine, P.V.; Nagpal, S.; Komm, B.S. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J. Steroid Biochem. Mol. Biol., 2010, 118, 117-124.
52. Lobo, R.A.; Pinkerton, J.V.; Gass, M.L.S. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil. Steril., 2009, 92, 1025-1038.
53. Shelly, W.; Draper, M.W.; Krishnan, V.; Wong, M.; Jaffe, R.B. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet. Gynecol. Surv., 2008, 63, 163-181.
54. Fadini, G.P.; Baesso, I.; Albiero, M.; Sartore, S.; Agostini, C.; Avogaro, A. Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau. Atherosclerosis, 2008, 197, 496-503.
55. Takahashi, T.; Kalka, C.; Masuda, H.; Chen, D.; Silver, M.; Kearney, M.; Magner, M.; Isner, J.M.; Asahara, T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med., 1999, 5, 434-438.
56. Albiero, M.; Menegazzo, L.; Avogaro, A.; Fadini, G.P. Pharmacologic targeting of endothelial progenitor cells, Cardiovasc. Hematol. Disord. Drug Targets, 2010, 10, 16-32.
57. Werner, N.; Kosiol, S.; Schiegl, T.; Ahlers, P.; Walenta, K.; Link, A.; Bohm, M.; Nickenig, G. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med., 2005, 353, 999-1007.
58. Schmidt-Lucke, C.; Rossig, L.; Fichtlscherer, S.; Vasa, M.; Britten, M.; Kamper, U.; Dimmeler, S.; Zeiher, A.M. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation, 2005, 111, 2981-2987.
59. Fadini, G.P.; de Kreutzenberg, S.; Agostini, C.; Boscaro, E.; Tiengo, A.; Dimmeler, S.; Avogaro, A. Low CD34+ cell count and metabolic syndrome synergistically increase the risk of adverse outcomes. Atherosclerosis, 2009, 207, 213-219.
60. Maruyama, S.; Taguchi, A.; Iwashima, S.; Ozaki, T.; Yasuda, K.; Kikuchi-Taura, A.; Soma, T.; Ishii, H.; Murohara, T.; Takahashi, H.; Kasuga, H.; Kumada, Y.; Toriyama, T.; Ito, Y.; Kawahara, H.; Yuzawa, Y.; Matsuo S. Low circulating CD34+ cell count is associated with poor prognosis in chronic hemodialysis patients. Kidney Int., 2008, 74, 1603-1609.
61. Shintani, S.; Murohara, T.; Ikeda, H.; Ueno, T.; Honma, T.; Katoh, A.; Sasaki, K.; Shimada, T.; Oike, Y.; Imaizumi, T. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation, 2001, 103, 2776-2779.
62. Hennemann, B.; Ickenstein, G.; Sauerbruch, S.; Luecke, K.; Haas, S.; Horn, M.; Andreesen, R.; Bogdahn, U.; Winkler, J. Mobilization of CD34+ hematopoietic cells, colony-forming cells and longterm culture-initiating cells into the peripheral blood of patients with an acute cerebral ischemic insult. Cytotherapy, 2008, 10, 303-311.
63. Santo, S.D.; Tepper, O.M.; von Ballmoos, M.W.; Diehm, N.; Volzmann, J.; Baumgartner, I.; Kalka, C. Cell-based therapy facilitates venous thrombus resolution. Thromb. Haemost., 2009, 101, 460-464.
64. Fadini, G.P.; Sartore, S.; Schiavon, M.; Albiero, M.; Baesso, I.; Cabrelle, A.; Agostini, C.; Avogaro, A. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia, 2006, 49, 3075-3084.
65. Fadini, G.P.; Agostini, C.; Sartore, S.; Avogaro, A. Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis, 2007, 194, 46-54.
66. Fadini, G.P.; Agostini, C.; Boscaro, E.; Avogaro, A. Mechanisms and significance of progenitor cell reduction in the metabolic syndrome. Metab. Syndr. Relat. Disord., 2009, 7, 5-10.
67. Fadini, G.P.; Sartore, S.; Albiero, M.; Baesso, I.; Murphy, E.; Menegolo, M.; Grego, F.; Vigili de Kreutzenberg, S.; Tiengo, A.; Agostini, C.; Avogaro, A. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 2140-6.
68. Iwakura, A.; Luedemann, C.; Shastry, S.; Hanley, A.; Kearney, M.; Aikawa, R.; Isner, J.M.; Asahara, T.; Losordo, D.W. Estrogenmediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation, 2003, 108, 3115-3121.
69. Iwakura, A.; Shastry, S.; Luedemann, C.; Hamada, H.; Kawamoto, A.; Kishore, R.; Zhu, Y.; Qin, G.; Silver, M.; Thorne, T.; Eaton, L.; Masuda, H.; Asahara, T.; Losordo, D.W. Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. Circulation, 2006, 113, 1605-1614.
70. Hamada, H.; Kim, M.K.; Iwakura, A.; Ii, M.; Thorne, T.; Qin, G.; Asai, J.; Tsutsumi, Y.; Sekiguchi, H.; Silver, M.; Wecker, A.; Bord, E.; Zhu, Y.; Kishore, R.; Losordo, D.W. Estrogen receptors 􀀁 and ß mediate contribution of bone marrow-derived endothelial progenitor cells to functional recovery after myocardial infarction. Circulation, 2006, 114(21), 2261-2270.
71. Fadini, G.P.; de Kreutzenberg, S.; Albiero, M.; Coracina, A.; Pagnin, E.; Baesso, I.; Cignarella, A.; Bolego, C.; Plebani, M.; Nardelli, G.B.; Sartore, S.; Agostini, C.; Avogaro, A. Gender differences in endothelial progenitor cells and cardiovascular risk profile: the role of female estrogens. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 997-1004.
72. Foresta, C.; Zuccarello, D.; Biagioli, A.; De Toni, L.; Prana, E.; Nicoletti, V.; Ambrosini, G.; Ferlin, A. Oestrogen stimulates endothelial progenitor cells via oestrogen receptor-􀀁. Clin. Endocrinol. (Oxf), 2007, 67, 520-525.
73. Imanishi, T.; Tsujioka, H.; Akasaka, T. Endothelial progenitor cell senescence - is there a role for estrogen? Ther. Adv. Cardiovasc. Dis., 2010, 4, 55-69.
74. Imanishi, T.; Hano, T.; Nishio, I. Estrogen reduces angiotensin IIinduced acceleration of senescence in endothelial progenitor cells. Hypertens. Res., 2005, 28, 263-271.
75. Imanishi, T.; Hano, T.; Nishio, I. Estrogen reduces endothelial progenitor cell senescence through augmentation of telomerase activity. J. Hypertens., 2005, 23, 1699-1706.
76. Bolego, C.; Rossoni, G.; Fadini, G.P.; Vegeto, E.; Pinna, C.; Albiero, M.; Boscaro, E.; Agostini, C.; Avogaro, A.; Gaion, R.M.; Cignarella, A. Selective estrogen receptor- agonist provides heart and vascular protection with enhanced endothelial progenitor cell mobilization in the absence of uterotrophic action. FASEB J doi: 10.1096/fj.09-139220. [Epub ahead of print].
77. Lebesgue, D.; Traub, M.; De Butte-Smith, M.; Chen, C.; Zukin, R.S.; Kelly, M.J.; Etgen, A.M. Acute administration of nonclassical estrogen receptor agonists attenuates ischemia-induced hippocampal neuron loss in middle-aged female rats. PLoS One., 2010, 5(1), e8642.